RxDoctor Payments Data

Magdy Elsakr, MD

Gastroenterology · Modesto, CANPI 1184676785

Payments from drug & device makers

$26,799in general payments, 2019–2025

Across 990 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$2K
  • Gilead$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $9K from 31 others

What the payments were for

  • Consulting fees$4,43217%
  • Travel & lodging$7973%
  • Food & beverage$21,46080%
  • Education$1100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,799 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$181,807
Medicare patients
510
Services billed
1,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$817,351
Humira PenAdalimumab25$175,814
CreonLipase/Protease/Amylase23$53,736
XifaxanRifaximin14$41,918
LinzessLinaclotide55$33,802
Dexlansoprazole DrDexlansoprazole61$21,786
Mesalamine39$18,493
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates159$10,685
Omeprazole527$6,226
Ursodiol15$4,372
MovantikNaloxegol Oxalate11$4,358
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl227$4,275
Pantoprazole Sodium219$3,101
Mesalamine ErMesalamine13$3,048
Rabeprazole Sodium175$2,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,859$817,35132 claims
AbbVieCreon, Linzess$5,469$87,53878 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,193$41,91814 claims
Redhill Biopharma Inc.Movantik$315$4,35811 claims
Braintree Laboratories, Inc.Sutab$397$1,93812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →